0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover194.59%IV-104.64%PremiumSep 20, 2024Expiry Date7.67Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9185Delta0.0498Gamma0.95Leverage Ratio-0.0112Theta-0.0046Rho-0.87Eff Leverage0.0025Vega
Biomea Fusion Stock Discussion
The pause on clinical trials seems to be a result of the explosion of industry regulations in recent years. From 2022 through 2024, the FDA has implemented "additional steps" to clinical trials, including bringing in outside agencies to help with oversight.
Red tape and bureaucracy, not BEMA, caused this pause. All the research I've done shows the pause was premature and overly cautious.
No comment yet